ESC Premium Access

SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes

Congress Presentation

About the speaker

Associate Professor Esteban Jodar Gimeno

Universitary Hospital Quironsalud Madrid, Pozuelo de Alarcon (Spain)
0 follower

4 more presentations in this session

State of the Art: cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

Speaker: Professor D. De Zeeuw (Groningen, NL)

Thumbnail

Risk of major cardiovascular events in patients with type 2 diabetes with and without prior cardiovascular events: results from the LEADER trial

Speaker: Professor N. Poulter (London, GB)

Thumbnail

Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE

Speaker: Doctor V. Menon (Cleveland, US)

Thumbnail

Cardiovascular outcome trials in type 2 diabetes: lessons learned and questions to ask.

Speaker: Professor L. Ryden (Stockholm, SE)

Thumbnail

Access the full session

Cardiovascular disease prevention with antihyperglycaemic and cholesterol lowering therapy in type 2 diabetes

Speakers: Associate Professor E. Jodar Gimeno, Professor D. De Zeeuw, Professor N. Poulter, Doctor V. Menon, Professor L. Ryden
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb